134 related articles for article (PubMed ID: 25626322)
1. [Immunomodulatory effects of lenalidomide].
Handa H; Saitoh T; Murakami H
Nihon Rinsho; 2015 Jan; 73(1):156-61. PubMed ID: 25626322
[TBL] [Abstract][Full Text] [Related]
2. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells.
Dauguet N; Fournié JJ; Poupot R; Poupot M
Cell Immunol; 2010; 264(2):163-70. PubMed ID: 20621290
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
[TBL] [Abstract][Full Text] [Related]
5. Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells.
Miyazato K; Tahara H; Hayakawa Y
Cancer Sci; 2020 Aug; 111(8):2770-2778. PubMed ID: 32573072
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
Payvandi F; Wu L; Naziruddin SD; Haley M; Parton A; Schafer PH; Chen RS; Muller GW; Hughes CC; Stirling DI
J Interferon Cytokine Res; 2005 Oct; 25(10):604-16. PubMed ID: 16241859
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
8. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Busch A; Zeh D; Janzen V; Mügge LO; Wolf D; Fingerhut L; Hahn-Ast C; Maurer O; Brossart P; von Lilienfeld-Toal M
Clin Exp Immunol; 2014 Aug; 177(2):439-53. PubMed ID: 24712857
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Görgün G; Calabrese E; Soydan E; Hideshima T; Perrone G; Bandi M; Cirstea D; Santo L; Hu Y; Tai YT; Nahar S; Mimura N; Fabre C; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Oct; 116(17):3227-37. PubMed ID: 20651070
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
D'Souza C; Prince HM; Neeson PJ
Front Immunol; 2021; 12():632399. PubMed ID: 33746969
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
12. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
[TBL] [Abstract][Full Text] [Related]
15. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
[TBL] [Abstract][Full Text] [Related]
16. Expansion of Th
Harada T; Miki H; Cui Q; Oda A; Amachi R; Teramachi J; Bat-Erdene A; Sogabe K; Iwasa M; Fujii S; Nakamura S; Kagawa K; Yoshida S; Endo I; Aihara K; Ozaki S; Matsumoto T; Abe M
Leukemia; 2017 Jan; 31(1):258-262. PubMed ID: 27698446
[No Abstract] [Full Text] [Related]
17. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
Sakamaki I; Kwak LW; Cha SC; Yi Q; Lerman B; Chen J; Surapaneni S; Bateman S; Qin H
Leukemia; 2014 Feb; 28(2):329-37. PubMed ID: 23765229
[TBL] [Abstract][Full Text] [Related]
18. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
19. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
